Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Authors : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)
Volume : 14

HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management.

Authors : Wolf S, Vercruyssen M, Cook L
Year : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 446-453

Highlights In Multiple Myeloma.

Authors : Meuleman N, Vercruyssen M
Year : 2021
Journal : Belgian J Hematology
Volume : 12(5)
Pages : 220-2

Primary gastric plasmatytoma: case report of a rare plasma cell neoplasm.

Authors : Rizzo O, Bron D, Vercruyssen M, de Wind A, Roelandts M, Eisendrath P, Lemmers A, Meuleman N
Year : 2021
Journal : Belgian J Hematology
Volume : 12(8)
Pages : 349–52

Adult T-cell leukaemia-lymphoma: Pathogeny and clinical recommendations.

Authors : Vercruyssen M, Van den Broeke A, Salaroli A, Nguyen P, de Wind A, Meuleman N, Bron D
Year : 2019
Journal : Belgian J Hematology
Volume : 10
Pages : 277-284

Long-term follow-up of 2 patients treated with 90Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.

Authors : Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D
Year : 2018
Journal : Eur J Haematol
Volume : 101
Pages : 415-417

Monoclonal gammopathy of undetermined significance : when and why to look for them ?

Authors : Meuleman N, Vercruyssen M
Year : 2018
Journal : Rev Med Brux
Volume : 39
Pages : 302-306

Diagnostic approach of an IgM monoclonal gammopathy and clinical importance of gene MYD88 L265P mutation.

Authors : Cilla N, Vercruyssen M, Ameye L, Paesmans M, de Wind A, Heimann P, Meuleman N, Bron D
Year : 2018
Journal : Rev Med Brux